
ISPOR List of Presentations

ISPOR 21st Annual European Congress, November 2018, Barcelona, Spain

MD1

Evidence Development Timeline of Medical Devices in the UK: Where do MedTech Innovation Briefings Fit?

Overhill A, Chen G, Upton E, Peirce V, Marsh W

PMD167

Health Technology Assessment of mHealth Applications: Slow Progress in a Fast-Paced Industry?

Ridley CJA, Tomlinson P, Marsh W

PMS66

Improving Patient and Financial Outcomes in the NHS: Early Arthritis Service Increases Patient Satisfaction Whilst Saving Costs

Nisar M, Tomlinson P, Taylor C, Beale R

PMD134

Medical Device Appraisal in the UK: What Are the Common Pitfalls of Manufacturer Literature Reviews?

Macnair P, Marsh W

PMD135

Determining Factors for Decision-Making in the Medical Technologies Evaluation Programme

Peirce V, Atkinson M, Marsh W

PRM109

Exploring the Use and Acceptance of Alternative Survival Modelling Approaches for Immuno-Oncology Therapies in UK Technology Assessments

Porteous A, van Hest N, Griffiths M, Morten P

ISPOR 20th Annual European Congress, November 2017, Glasgow, United Kingdom

IP9

Should Rare Oncology Treatments be Considered True Orphans?

Griffiths A, Gajraj E, Pantziarka P, Cattaneo I

MD4

Evaluating Matching-Adjusted Indirect Comparison and Simulated Treatment Comparison Techniques: Impact on Health-Related Quality of Life of Focussed Ultrasound Thalamotomy and Other Interventions for the Treatment of Medication-Refractory Essential Tremor

Langford BE, Ridley CJ, Beale RC, Marsh W, Caseby SC, Richard L

SY4

Do EU5 Countries with Favourable Healthcare Expenditure and Reimbursement Indicators have Better Patient Reported Access to Treatments for Rare Diseases?

Allen G, Hall A, Hanman K, Le Fevre R, Griffiths A

PCN201

No EQ-5D? Analysis of Alternative Utility Value Sources used in NICE Appraisals for Oncology Indications

Beale RC, Wickstead RM, Chen G, Walker E, Griffiths M

PHP3

Consumer Comments in Health Technology Assessment in Australia: How Common and Influential are They?

Viswambaram A, McManus K, Miah R, Miles G

PHP60

Health Technology Assessment in Singapore: Shining a Light in the Darkness

Viswambaram A, Brooks-Rooney C

PHP241

How do NICE Evidence Review Groups Perceive Single Technology Appraisals Presenting Limited Evidence of Comparative Treatment Efficacy?

Langford BE, Beaver S, Besford M, Castell A, Dierker Viik A, Eddowes LA

PHP247

When the Price is Right: When, in Practice, are Confidential Discounts Introduced in the NICE Process?

Noon K, Ulrich A, Painter C, Montgomery S

PHP262

An Audit of Evidence Review Group Criticisms of Systematic Literature Reviews Conducted to Inform Manufacturers' Submissions to the National Institute for Health and Care Excellence
Leonard S, Summers J, Young E

PHP300

Payers, Politics And Pandemonium: An Insight Into the Future UK Pricing and Market Access Environment
Spors J, Kusel J

PMD156

Does the NICE Diagnostics Assessment Programme Use an Empirical ICER Threshold?
Chen G, Koczula KM, Peirce VJ, Marsh W

PRM118

Model Types Submitted to NICE: What is Considered Appropriate by Evidence Review Groups?
Hearmon NC, Ghosh W, Buguth B, Kusel J

PRM242

An Exploration of the Methodology of Published Systematic Literature Reviews on "Burden of Disease"
Buchanan-Hughes AM, Beaver S, Fell B, Summers J, Young E

PSY148

Why do 'True' Orphan Medicines Have Such a Low Acceptance Rate When Assessed by the SMC?
Morten P, Ulrich A, Le Fevre R, Eddowes LA

ISPOR 22nd Annual International Meeting, May 2017, Boston, USA

PHP266

Value Frameworks to Set Tongues Wagging: Analysis of Opinions and Discussions on Key Value Frameworks
Koczula K, Noon K, Wickstead R, Ghosh W, Uchea C, Kusel J

PHS131

Inequity in Healthcare Access in Asian Countries with Reportedly High Universal Health Coverage Levels
Evans J, Ma C, Noon K, Steeves S

PMD74

Cost-Effectiveness of PET-CT Versus Adrenal Vein Sampling for the Diagnosis of Hypertension Caused by Primary Aldosteronism
Lin Z, Kusel J, Ghosh W, Brown M

PMD118

Small and Medium-Sized Enterprises: How Do They Fare in the UK Medical Technologies Evaluation Programme (MTEP)?
Ridley C, Marsh W

ISPOR 19th Annual European Congress, November 2016, Vienna, Austria

IP7

How Should Biosimilars be Valued and Should They Undergo Health Technology Assessment?
Kusel J, Psachoulia E, McKenna F, Walker A

IP21

Is Off-Label Drug Use Enhancing or Limiting Access for Patients with Rare Diseases?
Griffiths A, Scannell J, Timmis O, Pinilla-Dominguez P

PRM128

Pharmacological Interventions for Familial Hypercholesterolaemia in Children and Adolescents: An Exploratory Evaluation Using Advanced Hierarchical Network Meta-Analysis Techniques
Langford B, Wickstead R, Murphy D, Marsh W, Beale R, Evans J, Kusel J, Griffiths M

PRM210

Adapting to the Challenge: How are Innovative Study Designs Being Used in Rare Diseases?
Berry L, Eddowes L

PIN70

Health State Utility Values Measured Using the EuroQol 5-Dimensions Questionnaire in Adults with Chronic Hepatitis C: A Systematic Literature Review
Buchanan-Hughes A, Hanman K, Langford B, Eddowes L

PHP6

Patient Group Submissions in Health Technology Assessment in Scotland: Prevalence and Impact
Hamilton K, Hanman K, Griffiths M

PHP94

Do Scottish Formulary Decisions Match Recommendations Made by the SMC?
Beale R, Kusel J

PCV16

Pharmacological Interventions for Familial Hypercholesterolaemia in Children and Adolescents: A Systematic Literature Review
Wickstead R, Evans J, Langford B, Beale R, Marsh W, Kusel J, Griffiths M

PSY156

A Value for Money Threshold for New Technologies for Very Rare Conditions: Does the NICE Highly Specialised Technology Committee Employ One?
Kusel J, Griffiths A, Spoors J

PCN236

Innovative Therapies for the Treatment of Cancer: An Overview of Late-Phase Clinical Development
Resemann H, Chainani N, Morten P, Griffiths M

PCN294

Reconsidering Drugs Funded via the Cancer Drugs Fund in England: What's New This Time?
Morten P, Lin Z, Kusel J

PMD23

Cost of Ebola Virus Disease Diagnosis Using Rapid Point-of-Care Diagnostics in Sierra Leone
Evans J, Hearmon N, Beale R, Marsh W

PMD59

Investigating the Cost-Effectiveness of Genetic Counselling for Couples at Known Risk of Having Children with Tay-Sachs Disease: A Two-Generation Model
Ghosh W, Griffiths M, Griffiths A

ISPOR 7th Asia-Pacific Conference, September 2016, Singapore

IP3

Joint HTA: The Next Step for the ASEAN Economic Community?
Chen G, Ngorsurachet S, Redekop K

IP15

Should Productivity Losses due to Illness be Considered in Health Economic Evaluations?
Brooks-Rooney C, Redekop K, Wee HL, Milea D

PCV33

Measurement of Adherence to Anti-Hypertensive Drugs in Asia
Ma Q, Kao C, Miles G, Chen G

PCV54

Quantifying Informal versus Formal Care, and Financial Caregiver Burden, for Stroke Patients in Asia: A Structured Literature Review
Wayman S, Langford B, Buchanan-Hughes A, Chen G

PHP38

Universal Health Coverage in Countries across East and South East Asia – Associations between Health Expenditure and Service Provision
Evans J, Wickstead R, Hanman K, Steeves S

PIN15

Economic Burden of Antibiotic-resistant Nosocomial Gram-Negative Bacteraemia in Singapore Hospitals
Chen G, Lim S, Ma Q, Kao C, Ghosh W

PMH16

Estimating the Economic Impact due to Productivity Losses of Diabetes and Major Depressive Disorder in Singapore: Human Capital versus Friction Cost Approaches
Brooks-Rooney C, Griffiths M, Chen G

ISPOR 21st Annual International Meeting, May 2016, Washington DC, USA

PHP54

The Trade-Off Between QALY Maximisation and Social Values: A Systematic Review of Public Opinion Surveys

Buchanan-Hughes A, Kusel J

ISPOR 18th Annual European Congress, November 2015, Milan, Italy

PCN323

Does Budget Impact Affect Reimbursement Decisions Made by the Cancer Drugs Fund in England?

Stewart G, Kusel J, Montgomery S

PUK15

Investigating the Cost-Effectiveness of Bacterial Whole-Genome Sequencing for Enabling Targeted Antibiotic Selection in Urinary Tract Infections

Buchanan-Hughes A, Griffiths A, Evans J, Slater D, Eddowes L

PDB116

The Role of Education in the Management of Type 1 Diabetes Mellitus in England

Toth C, Marsh W, Stewart G, Yang L, Bridges H, Kusel J

PRM237

Using Incentives to Improve Health-Related Behaviours: A Review of Incentive-Based Trials

Bunting C, Lim S, Morten P

PRM267

Development of a PRECIS-2 Scoring Grid: How Pragmatic are Pragmatic Trials of Surgical and Pharmaceutical Interventions?

Chen G, Ma Q, Yang L, Ghosh W, Kusel J

PRM55

Hunting for Randomised Controlled Trials (RCTs): A Comparison of Search Filters Designed to Identify RCTs

Steeves S, Buchanan-Hughes A, Evans J, Leonard S

ISPOR 5th Latin America Conference, September 2015, Santiago, Chile

IP2

Disinvestment in Latin America: What are the Experiences, Challenges and Proposals for its Successful Implementation?

Agirrezabal I, Rodríguez A, Esandi ME, Gutiérrez-Ibarluzea I

PP4

An Undeveloped Picture: The Availability of Utility Valuations in Latin America. How Will They Affect QALYs?

Montgomery S, Stewart G, Kusel J

PHP23

Pharmaceutical Cost-Containment Strategies – Opinions of the Pharmaceutical Industry and HTA Bodies in Latin America

Beale R, Stewart G, Agirrezabal I, Kusel J

PHP24

Immunisation in Latin America: Factors Preventing Uptake of Cost-Effective Vaccines

Burton J, Bunting C, Eddowes LA, Wilson T

PHP38

Considerations for the Adoption of the WHO-CHOICE Cost-Effectiveness Threshold in Latin America

Griffiths M, Latchford J, Stewart G, Kusel J

PHP40

Clinical Trial Trends in Latin America: Communicable Versus Non-Communicable Disease

Anderson R, Wilson T

PHP54

Disinvestment Initiatives in Latin America: A Systematic Literature Review

Agirrezabal I, Latchford J, Gutierrez-Ibarluzea I

PRM9

A Systematic Review of Economic Evaluations in Latin America: Assessing the Factors That Affect Adaptation and Transferability of Results

Stewart G, Slater D, Maruszczak M

ISPOR 20th Annual International Meeting, May 2015, Philadelphia, USA

PMD34

A System Dynamics Model for the Cost-effectiveness Evaluation of Bacterial Whole-genome Sequencing for Detecting and Monitoring Outbreaks of MRSA
Agirrezabal I, Buchanan-Hughes A, Eddowes L, Luheshi L, Sagoo GS, Török ME

PMD37

A System Dynamics Model for the Cost-effectiveness Evaluation of Bacterial Whole-genome Sequencing for Monitoring Outbreaks of Clostridium difficile
Buchanan-Hughes A, Agirrezabal I, Eddowes L, Luheshi L, Török ME, Sagoo GS

PRM28

Implication of the Inter-relatedness of the Proportional and Absolute QALY Shortfall Measurements for Disease Burden
Kusel J, Beale R, Maruszczak M

PHP107

The WHO-Choice Cost-effectiveness Threshold: A Country-level Analysis of Changes Over Time
Griffiths M, Maruszczak M, Kusel J

ISPOR 17th Annual European Congress, November 2014, Amsterdam, The Netherlands

W5

Value-based Assessment for NICE: How to Do the Calculations
Kusel J, Boysen M, Hatswell AJ, Shah K

HS3

Impact of Morbidity in Populations of North London Clinical Commissioning Groups on Patient Admission Rates and GP Referrals
Groom ZC, Burgon J, Eddowes LA, Wilson T, Kusel J

QA1

Economic Orphans? The Prevalence of Child-specific Utilities in NICE Appraisals for Paediatric Indications
Montgomery S, Hassan M, Kusel J

NI2

Predicting the Impact of Value-based Assessment on Future NICE Appraisals
Beale RC, Maruszczak M, Kusel J

PGI17

A Cost of Care Model for Inflammatory Bowel Disease with a UK NHS Perspective
Miles G, Leonard SA, Ghosh N, Premchand P

PND49

Expected Value of Partial Perfect Information for the Disability Progression Efficacy of Teriflunomide and Fingolimod in the Treatment of Relapsing-remitting Multiple Sclerosis
Maruszczak M, Kusel J, Adlard N

PMH63

Antidepressant Use and Suicide Rate in England: The Geographic Divide
Anderson R, Wilson T, Griffiths M

PRM124

Discrete Event Simulation for the Cost-effectiveness Evaluation of PET-CT Scans in the Diagnosis of Conn's Disease in Hypertensive Patients
Maruszczak M, Stewart G, Kusel J, Brown MJ

PRM28

Systematic Review and Critique of Health Economic Models of Relapsing-remitting Multiple Sclerosis in the UK
Kusel J, Maruszczak M, Montgomery S, Allen F, Adlard N

PCN260

Investigating the Use of Personalised Medicine in Cancer Trials – An Update
Hamilton K, Wilson T

ISPOR 6th Asia-Pacific Conference, September 2014, Beijing, China

IP2

Disinvestment in Asia-Pacific: How Can This Be Implemented in HTA and What Can Be Learnt from Europe?

Brooks-Rooney C, Kamae I, Tan ST, Gutiérrez-Ibarluzea I

QA2

An Analysis of New Health Technologies and Reimbursement Pricing Structure in Taiwan

Stewart G, Brooks-Rooney C

PCN13

Analysing the Effects of a Disinvestment Decision in Breast Cancer Screening Programmes in Asia-Pacific Countries: A Modelling Approach

Agirrezabal I, Bunting C, Brooks-Rooney C

PCN39

The Differences Between Cancer Drug Approvals in Japan and the USA

Anderson R, Brooks-Rooney C

PDB9

Impact of Ethnicity on the Efficacy and Safety Outcomes of Anti-Diabetes Drugs – Case Study of Liraglutide in Asian and Non-Asian Populations

Chen G, Yang L, Lantaff B, Kusel J, Warnakula S, Brooks-Rooney C

PMS30

Closing the Gap: Reduced Delay to Drug Marketing Approval Between the West and Asia

Hamilton KI, Eddowes LA, Brooks-Rooney C

PIN33

The Differences Between Infectious & Parasitic Drug Approvals in Japan and the USA

Anderson R, Brooks-Rooney C

ISPOR 19th Annual International Meeting, May 2014, Montreal, Canada

HC2

The Impact of NICE's End-Of-Life Threshold on the Availability of New Cancer Therapies in England and Wales

Stewart G, Eddowes L, Hamerslag L, Kusel J

PHP27

An Update on How NICE Manage Off-Label Comparators

Kusel J, Steeves S, Maruszczak M, Pettit L, Wilson T, Taylor D

PGI30

Patterns of Generic and Proprietary Prescribing of Proton Pump Inhibitors (PPIs) Over Time in England

Hamilton K, Kusel J, Leonard S

PDB128

Insulin Pumps for the Treatment of Type 1 Diabetes Mellitus: Why is Uptake so Low in the UK?

Marsh W, Wilson T, Kusel J

ISPOR 16th Annual European Congress, November 2013, Dublin, Ireland

IP13

Should Off-Label Agents Be Used as Comparators in Health Technology Assessments?

Kusel J, Walker W, Spackman E, Andersson C

PCN207

Impact of Recommended Pharmaceuticals on Cancer Mortality: Analysis of Real-Life Data

Wilson T, Hamerslag L, Kusel J

PHP152

The Relationship Between Scientific Research, Clinical Trials and FDA Drug Approval

Burgon J, Hamerslag L

PHP166

How Does the Uncertainty Around the Expected ICER Affect NICE Decisions?

Barber R, Steeves S, Wilson T, Hamerslag L, Kusel J

PMH68

How Well Do We Understand the Economic Burden Associated with Dementia? A Focus on Trends in Care Home Costs and Future Perspectives in the UK

Griffiths M, Hamerslag L, Wilson T, Stewart G, Kusel J

PMS27

Global Variations in Biologics Access and Rheumatoid Arthritis Treatment Costs

Miles G, Bell J, Wilson T, Hamerslag L, Kusel J

ISPOR 18th Annual International Meeting, May 2013, New Orleans, USA

PSY89

Treatment Options in Obesity: Is Clinical Development Keeping up with an Expanding Population?

Hay J, Barber R, Kusel J, Wilson T

PMS48

Quality of Life in Rheumatoid Arthritis: How Much Do We Really Know?

Miles GA, Rolfe F, Kusel J, Brooks-Rooney C, Hay J

PHP104

Assessing the Implementation of NICE Guidance: Is There a Correlation Between Recommendations and Uptake in Clinical Practice

Pettit L, Leonard S, Brooks-Rooney C, Hamerslag L, Kusel J

ISPOR 15th Annual European Congress, November 2012, Berlin, Germany

NI2

The Use of Off-Label Comparators in NICE Appraisals – An Indirect Endorsement?

Kusel J, Wong GK, Hay JA, Pettit LJ

CA2

Applying a Value-Based Price Across Different Disease Areas

Wilson TJ, Kusel J, Brooks-Rooney C, Costello S

PCN144

Access to Cancer Interventions Across the UK: To What Extent Does SMC Advice Agree with NICE's End-of-Life Therapies?

Hamerslag L, Brooks-Rooney C, Zhou A, Pettit L

ISPOR 5th Asia-Pacific Conference, September 2012, Taipei, Taiwan

HC4

Tapping into the Asian Pharmaceutical Market: Global Firms Go Local?

Wong GKW, Brooks-Rooney C, Hamerslag L, Timm B, Wilson TJ, Costello S

PHP82

The Characteristics of Clinical Trials in Asia
Brooks-Rooney C, Wong GKW, Hamerslag L, Costello S

PRM11

The Use of Biomarkers in Cancer Trials in Asia
Hamerslag L, Wilson T, Brooks-Rooney C

ISPOR 17th Annual International Meeting, June 2012, Washington DC, USA

PCN148

The Use of Personalised Medicine in Cancer Trials
Wilson TJ, Hamerslag L, Kusel J, Brooks-Rooney C, Rolfe F, Costello S

PHP66

Assessing Agreement Between Patient Access Schemes: Review of NICE and SMC Guidance
Timm B, Leonard S, Haynes S

PRM11

The Rise of Budget Impact Analyses – Another Hurdle in the Health Technology Approval Process?
Wong GKW, Hamer N, Wilson T, Costello S

ISPOR 14th Annual European Congress, November 2011, Madrid, Spain

RS2

Cost-effectiveness of End-of-life, Life-extending Interventions: NICE's Cost-effectiveness Threshold Explored

Hamerslag L, Haynes S, Kusel J, Costello S

RS4

The Interim Cancer Drugs Fund – How To Not Spend £50 Million

Timm B, Brooks-Rooney C, Hamerslag L, Costello S

PHP123

To What Extent Does Advice From the SMC Agree with that Published by NICE?

Leonard SA, Brooks-Rooney C, Kusel J, Costello S

PHP145

The Burden of Evidence in the Pharmaceutical Appraisal Process

Hamer N, Brooks-Rooney C, Timm B, Leonard S, Costello S

PHP152

The Administrative Burden of Patient Access Schemes in the Changing UK Healthcare System: A Follow Up Study

Haynes S, Timm B, Hamerslag L, Wong G, Costello S

PRM9

What Guidance is Available for Budget Impact Analysis?

Kusel J, Leonard S, Wilson T, Costello S

ISPOR 16th Annual International Meeting, May 2011, Baltimore, MD, USA

PRM3

The Burden of Caregiving: Assessing the Status of Current Clinical Research

Hamer N, Costello S, Hamerslag L, Haynes S, Roper S

PHP5

Incentive-based Interventions – Rewarding Patients for Good Behaviour

Haynes S, Costello S, Brooks-Rooney C, Hamer N

PHP7

Developing Public Health Guidance - What are the Data Gaps? Review of the Gaps in the Evidence Identified by NICE in the UK

Kusel J, Hamer N, Roper S, Hamerslag L, Costello S

PHP43

The Influence of Patient Access Schemes on Appraisal Decisions by NICE in the UK

Timm B, Kusel J, Hamer N, Brooks-Rooney C, Costello S

PHP89

The Implementation of Public Health Guidance: Preference for Clinical over Behavioural Interventions

Hamerslag L, Kusel J, Haynes S, Brooks-Rooney C, Costello S

PMS69

The Use of Mixed Treatment Comparisons in NICE Technology Appraisals

Brooks-Rooney C, Costello S, Kusel J, Timm B

ISPOR 13th Annual European Congress, November 2010, Prague, Czech Republic

NI4

Do Patient Access Schemes Result in an Acceptable Administrative Burden?

Haynes S, Costello S, Brooks-Rooney C, Hamer N

PHP94

Is it Cost-Effective to Change the Behaviour of Healthcare Professionals?

Kusel J, Costello S, Haynes S, Brooks-Rooney C, Hamer N, Timm B

PHP98

Cost-Effectiveness Methodologies of Strategies that Aim to Change the Behaviour of Healthcare Professionals

Kusel J, Costello S, Haynes S, Brooks-Rooney C, Hamer N, Timm B

ISPOR 15th Annual International Meeting, May 2010, Atlanta, GA, USA

PHP79

Innovative Pricing Agreements in UK NICE Submissions

Costello S, Haynes S, Kusel J, Brooks-Rooney C, Hamer N